February has several important catalysts for companies in the biotech; these have the potential to move these stocks significantly in the short term. Dynavax is going in front of a CDC advisory committee in search of a recommendation for Heplisav-B, its adult Hepatitis B vaccine. Novavax will be reporting …
0 Comments